Primary completion for a Phase 3 study of guselkumab (Tremfya) in participants with moderately to severely active Crohn's disease was announced on 2023-07-04. The trial results indicated that 56.1% of participants receiving guselkumab 400 mg achieved clinical remission at Week 12, compared to 21.4% in the placebo group.
Background
Guselkumab is being investigated for the treatment of moderately to severely active Crohn's disease, a chronic inflammatory bowel condition.
Trial design
The Phase 3 study (NCT05197049) evaluated subcutaneous guselkumab therapy in 350 participants with moderately to severely active Crohn's disease. The trial compared various doses of guselkumab (dose 1, dose 2, dose 3) against placebo to assess its efficacy and safety.
Key results
The trial results demonstrated significant improvements across several endpoints:
- At Week 12, 56.1% of participants in the Combined: Guselkumab 400 mg group achieved clinical remission, compared to 21.4% in the Placebo group. The adjusted treatment difference was 34.9 percentage points (95% CI: 25.1 to 44.6; p-value: 0.001).
- For endoscopic response at Week 12, 41.3% of participants in the Combined: Guselkumab 400 mg group responded, versus 21.4% in the Placebo group. This represented an adjusted treatment difference of 19.9 percentage points (95% CI: 10.2 to 29.6; p-value: 0.001).
- Patient-reported outcome (PRO)-2 remission at Week 12 was achieved by 49.1% in the Combined: Guselkumab 400 mg group versus 17.1% for Placebo. The adjusted treatment difference was 32.1 percentage points (95% CI: 22.9 to 41.2; p-value: 0.001).
- Clinical response at Week 12 was observed in 73.5% of participants in the Combined: Guselkumab 400 mg group, compared to 33.3% in the Placebo group. The adjusted treatment difference was 40.3 percentage points (95% CI: 29.9 to 50.7; p-value: 0.001).
- At Week 24, clinical remission was achieved by 60.9% of participants receiving Guselkumab 400 mg + 100 mg and 58.3% receiving Guselkumab 400 mg + 200 mg, compared to 21.4% in the Placebo group. The adjusted treatment difference for Guselkumab 400 mg + 100 mg was 37.0 percentage points (95% CI: 25.6 to 48.4; p-value: 0.001), and for Guselkumab 400 mg + 200 mg was 39.3 percentage points (95% CI: 28.0 to 50.7; p-value: 0.001).
- Regarding safety, 65.8% of participants in the Placebo group experienced Treatment-Emergent Adverse Events (TEAEs) through Week 48.
What this means
The positive results from this Phase 3 trial suggest that guselkumab may offer a significant therapeutic option for patients with moderately to severely active Crohn's disease. The observed improvements in clinical remission, endoscopic response, and patient-reported outcomes at both Week 12 and Week 24 indicate a robust efficacy profile. The consistent statistical significance (p-value: 0.001 for all reported analyses) across multiple endpoints highlights the potential of guselkumab to provide meaningful relief for patients suffering from this chronic condition. Further details on the safety profile of the active treatment arms, beyond the placebo group's TEAEs, would provide a more complete picture for clinical assessment.
Source
The information regarding the primary completion and results of this Phase 3 trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The data for study NCT05197049, titled 'A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease', was posted on 2023-07-04 on clinicaltrials.gov.